Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medlab Announces Favourable Interim Readout of Nanabis Real-World Evidence (RWE) Medcare Study
Details : NanaBis™ (tetrahydrocannabinol) is an investigative novel analgesic for cancer patients comprising equal parts of CBD and THC encapsulated in Medlab’s patented delivery platform, NanoCelle®. NanaBis™ is applied to the oro-buccal membrane for rapid...
Product Name : NanaBis
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration
Government Grant to Apply NanoCelle® to an RNA Nasal Vaccine
Details : This Government Grant & Academic collaboration solidify Medlab’s transition to a true Biotech company. The NanoCelle® non-invasive nasal delivered vaccine is considered a “first in class” medicine delivery system.
Product Name : NanoCelle
Product Type : Vaccine
Upfront Cash : Undisclosed
January 14, 2022
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Macquarie University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2021
Reset All
